Return to homepagePandemic Pact

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3UM1AI068636-16S1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2023

  • Known Financial Commitments (USD)

    $71,500,000

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    PROFESSOR Judith Currier

  • Research Location

    United States of America

  • Lead Research Institution

    UNIVERSITY OF CALIFORNIA LOS ANGELES

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 3 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Individuals with multimorbidity

  • Occupations of Interest

    Unspecified

Abstract

Abstract This supplement will support ACTIV-2D ACTIV-2D is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with SARS-CoV-2 infection. The protocol is a phase III multicenter, randomized, double blind trial to evaluate the safety and efficacy of S-217622 for the treatment of symptomatic high-risk non-hospitalized adults with SARS-CoV-2 infection. The primary outcome is to determine if the investigational agent (S-217622) will prevent the composite endpoint of hospitalization due to any cause or death due to any cause through study Day 29. Hospitalization is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic.